Home/Pipeline/AM-510

AM-510

Opioid Use Disorder

DiscoveryActive

Key Facts

Indication

Opioid Use Disorder

Phase

Discovery

Status

Active

Company

Aion Medicines

About Aion Medicines

Aion Medicines is a private, preclinical-stage biotech tackling the chronic disease epidemic through an ultra-long-acting drug delivery platform. Its primary asset, AM-710, is a small-molecule GLP-1R agonist in development for type 2 diabetes and obesity with potential dosing intervals of three to six months or longer, aiming for a best-in-class profile. The company is led by a team with deep drug development experience and is supported by a high-profile scientific advisory board. Aion operates in a pre-revenue stage, targeting massive markets with significant unmet needs in patient adherence.

View full company profile

Therapeutic Areas

Metabolic Disease Addiction Medicine

Other Opioid Use Disorder Drugs

Drug	Company	Phase	Status
TRV734	Trevena	Phase 1	Active
FP-004 (SIF Formulation)	Foresee Pharmaceuticals	Preclinical	Active
Vaxine Opioid Addiction Vaccine	Vaxine	Preclinical	Active
Safer Ibogaine Analogs	Gilgamesh Pharmaceuticals	Pre-clinical/Research	Active (NIDA Grant Funded)
Naltrexone Implant	Delpor	Phase 1	Active
Platform Expansion	Amygdala Neurosciences	Research	Active
Undisclosed OUD Program	Epiodyne	Pre-clinical	Active
AQL™-Naltrexone	Plumb Pharmaceuticals	Pre-clinical	Active
MEB-1170	Mebias Discovery	Phase 1	Active
SUBLOCADE®	Indivior PLC	Marketed	Commercial